Charles Schwab Investment Management Inc Sellas Life Sciences Group, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 16,238 shares of SLS stock, worth $19,323. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,238
Previous 16,238
-0.0%
Holding current value
$19,323
Previous $19,000
5.26%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SLS
# of Institutions
39Shares Held
5.69MCall Options Held
1.67MPut Options Held
74.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$2.73 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX794KShares$944,6630.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$720,1770.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$512,1370.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$367,0743.71% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $24.5M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...